title: Reduction of Streptococcus pneumoniae Colonization and Dissemination by a Nonopsonic Capsular Polysaccharide Antibody.
abstract: Streptococcus pneumoniae colonization of the nasopharynx (NP) is a prerequisite for invasive pneumococcal disease (IPD). The marked reduction in IPD that followed the routine use of pneumococcal polysaccharide conjugate vaccines (PCVs) has been linked to reduced NP colonization with vaccine-included serotypes (STs), with the caveat that PCVs are less effective against pneumonia than against IPD. Although PCV-elicited opsonic antibodies that enhance phagocytic killing of the homologous ST are considered a key correlate of PCV-mediated protection, recent studies question this relationship for some STs, including ST3. Studies with monoclonal antibodies (MAbs) to the pneumococcal capsular polysaccharide (PPS) of ST3 (PPS3) have shown that nonopsonic, as well as opsonic, antibodies can each protect mice against pneumonia and sepsis, but the effect of these types of MAbs on NP colonization is unknown. In this study, we determined the effects of protective opsonic and nonopsonic PPS3 MAbs on ST3 NP colonization in mice. Our results show that a nonopsonic MAb reduced early NP colonization and prevented ST3 dissemination to the lungs and blood, but an opsonic MAb did not. Moreover, the opsonic MAb induced a proinflammatory NP cytokine response, but the nonopsonic MAb had an antiinflammatory effect. The effect of the nonopsonic MAb on colonization did not require its Fc region, but its antiinflammatory effect did. Our findings challenge the paradigm that opsonic MAbs are required to prevent NP colonization and suggest that further studies of the activity of nonopsonic antibodies could advance our understanding of mechanisms of PCV efficacy and provide novel correlates of protection.
  
  
  OBJECTIVE
  Pneumococcal conjugate vaccines (PCVs) have markedly reduced the incidence of invasive pneumococcal disease (IPD). Vaccine-elicited pneumococcal polysaccharide (PPS) antibodies that enhance in vitro phagocyte killing of vaccine-included serotypes (STs) (opsonic antibodies) have been considered correlates of vaccine protection and are thought to exert their effect at the initial site of infection, the nasopharynx (NP). However, the data presented here show that this is not the necessarily the case. A nonopsonic PPS monoclonal antibody (MAb) reduced pneumococcal colonization and dissemination of its homologous ST in mice, but surprisingly, an opsonic PPS MAb to the same ST did not. These results reveal that PPS antibodies can work in different ways than previously thought, challenge the paradigm that opsonic antibodies are required to prevent IPD, and provide new insights into PCV efficacy that could lead to novel correlates of vaccine protection.
authors.affiliation: Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA.
authors.forename: Christopher R
authors.initials: CR
authors.lastname: Doyle
authors.affiliation: Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, USA l.pirofski@einstein.yu.edu.
authors.forename: Liise-anne
authors.initials: LA
authors.lastname: Pirofski
mesh_terms: D000818:Animals; D000907:Antibodies, Bacterial / Q000276:immunology*; D002353:Carrier State / Q000382:microbiology / Q000517:prevention & control*; D051379:Mice; D009305:Nasopharynx / Q000382:microbiology*; D009895:Opsonin Proteins / Q000276:immunology; D011008:Pneumococcal Infections / Q000382:microbiology / Q000517:prevention & control*; D011135:Polysaccharides, Bacterial / Q000276:immunology*; D013296:Streptococcus pneumoniae / Q000276:immunology*
chemical_list: D000907:Antibodies, Bacterial; D009895:Opsonin Proteins; D011135:Polysaccharides, Bacterial
references.citation: J Infect Dis. 2014 Nov 15;210(10):1658-69
references.pmid: 25001458
references.citation: Clin Vaccine Immunol. 2014 Sep;21(9):1277-81
references.pmid: 24990907
references.citation: Mucosal Immunol. 2015 Jan;8(1):176-85
references.pmid: 24962092
references.citation: Lancet Infect Dis. 2015 Mar;15(3):301-9
references.pmid: 25656600
references.citation: Infect Immun. 2015 Apr;83(4):1674-83
references.pmid: 25667263
references.citation: N Engl J Med. 2015 Mar 19;372(12):1114-25
references.pmid: 25785969
references.citation: Vaccine. 2015 Oct 26;33(43):5854-60
references.pmid: 26362099
references.citation: J Clin Invest. 2010 Apr;120(4):1355-61
references.pmid: 20335660
references.citation: Clin Exp Immunol. 1999 Dec;118(3):402-7
references.pmid: 10594558
references.citation: Nat Rev Mol Cell Biol. 2002 Dec;3(12):944-55
references.pmid: 12461560
references.citation: N Engl J Med. 2003 May 1;348(18):1737-46
references.pmid: 12724479
references.citation: N Engl J Med. 2003 May 1;348(18):1747-55
references.pmid: 12724480
references.citation: Vaccine. 2003 Jul 4;21(23):3265-72
references.pmid: 12804857
references.citation: Lancet. 2003 Aug 2;362(9381):355-61
references.pmid: 12907008
references.citation: Infect Immun. 2003 Dec;71(12):6775-83
references.pmid: 14638763
references.citation: Lancet Infect Dis. 2004 Mar;4(3):144-54
references.pmid: 14998500
references.citation: BMC Infect Dis. 2004 Jun 30;4:21
references.pmid: 15228629
references.citation: Nat Rev Microbiol. 2004 Sep;2(9):695-703
references.pmid: 15372080
references.citation: J Allergy Clin Immunol. 1975 Aug;56(2):141-51
references.pmid: 239050
references.citation: J Infect Dis. 1995 Jun;171(6):1387-98
references.pmid: 7769272
references.citation: Clin Diagn Lab Immunol. 1997 Jul;4(4):415-22
references.pmid: 9220157
references.citation: Vaccine. 1997 Aug;15(11):1261-8
references.pmid: 9286054
references.citation: Clin Vaccine Immunol. 2006 Feb;13(2):165-9
references.pmid: 16467321
references.citation: Clin Microbiol Rev. 2006 Jul;19(3):571-82
references.pmid: 16847087
references.citation: Infect Immun. 2007 Jan;75(1):83-90
references.pmid: 17088346
references.citation: Infect Immun. 2007 Apr;75(4):1643-50
references.pmid: 17220309
references.citation: Infect Immun. 2007 Apr;75(4):1801-10
references.pmid: 17261616
references.citation: Clin Vaccine Immunol. 2007 Apr;14(4):382-90
references.pmid: 17301214
references.citation: Infect Immun. 2009 Apr;77(4):1502-13
references.pmid: 19168739
references.citation: J Infect Dis. 2010 Jan 1;201(1):32-41
references.pmid: 19947881
references.citation: Clin Vaccine Immunol. 2010 May;17(5):713-21
references.pmid: 20200186
references.citation: Clin Infect Dis. 2010 Sep 15;51(6):692-9
references.pmid: 20715907
references.citation: Vaccine. 2010 Nov 3;28(47):7542-50
references.pmid: 20800700
references.citation: PLoS Pathog. 2010;6(11):e1001191
references.pmid: 21085613
references.citation: Clin Vaccine Immunol. 2011 Jan;18(1):59-66
references.pmid: 21068211
references.citation: Proc Am Thorac Soc. 2011 Mar;8(1):31-9
references.pmid: 21364219
references.citation: Expert Rev Vaccines. 2011 Mar;10(3):307-22
references.pmid: 21434799
references.citation: MBio. 2011;2(3):e00042-11
references.pmid: 21610121
references.citation: J Immunol. 2011 Jul 1;187(1):434-40
references.pmid: 21646297
references.citation: MBio. 2011;2(5). pii: e00176-11. doi: 10.1128/mBio.00176-11
references.pmid: 21917597
references.citation: Annu Rev Microbiol. 2011;65:563-81
references.pmid: 21721938
references.citation: Lancet Infect Dis. 2011 Oct;11(10):760-8
references.pmid: 21621466
references.citation: Cell Host Microbe. 2011 Nov 17;10(5):486-96
references.pmid: 22100164
references.citation: Clin Vaccine Immunol. 2011 Dec;18(12):2161-7
references.pmid: 21994351
references.citation: Pediatr Infect Dis J. 2012 Jan;31(1):72-7
references.pmid: 21960186
references.citation: Infect Immun. 2012 Apr;80(4):1314-22
references.pmid: 22290146
references.citation: Expert Rev Vaccines. 2012 Jul;11(7):841-55
references.pmid: 22913260
references.citation: J Immunol. 2013 Jan 1;190(1):317-23
references.pmid: 23233725
references.citation: Nat Rev Microbiol. 2014 Apr;12(4):252-62
references.pmid: 24590244
references.citation: Cell Host Microbe. 2014 Jul 9;16(1):55-67
references.pmid: 25011108
references.citation: Lancet Infect Dis. 2014 Sep;14(9):839-46
references.pmid: 25042756
references.citation: J Immunol. 2014 Nov 15;193(10):5190-8
references.pmid: 25320279